Seasonal Variation in Flares of Inflammatory Bowel Disease in a Korean Population

Jae Hyun Jang; Su Hee Lee; Jun Mo Sung; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Il Park
April 2012
Intestinal Research;2012, Vol. 10 Issue 2, p161
Academic Journal
Background/Aims: Conflicting data have been reported about the seasonal variation in flare-up of inflammatory bowel disease (IBD). The aim of this study was to assess the occurrence of seasonal variations in flare-up of IBD in the Korean population. Methods: Patients with IBD, who underwent more than 1 year of follow-up and showed more than 1 episode of flare-up, were included. Flares of disease were refined as follows; receipt of a new prescription and increasing dose of corticosteroids, 5-ASA or immunosuppressant; hospitalized or operated due to development and worsening of symptoms; elevation of inflammatory marker due to worsening of Crohn's Disease Activity Index (CDAI) or Mayo score. In addition, for patients with more than two episodes of flare-up, they were investigated in a monthly and seasonal pattern. Results: Of 573 patients with IBD, 46 patients with Crohn's disease and 61 patients with ulcerative colitis were enrolled. There was no association between month of the year and flare of Crohn's disease (P=0.06) or ulcerative colitis (P=0.58). Further, no association between season of the year and flare of Crohn's disease (P=0.06) or ulcerative colitis (P=0.68). However, in Crohn's disease who experience 2 or more flare-ups, symptoms occurred more frequently during winter, especially December (P=0.029). Conclusions: In the Korean population, there was no association of seasonal and monthly variation in flares of Crohn's disease and ulcerative colitis. However, in Crohn's disease, individuals with 2 flar-up or more, symptoms occurred more frequently during December.


Related Articles

  • Cytokine and Anti-cytokine Therapies for Inflammatory Bowel Disease. Ogata, Haruhiko; Hibi, Toshifumi // Current Pharmaceutical Design;May2003, Vol. 9 Issue 14, p1107 

    Although the pathogenesis of inflammatory bowel disease (IBD) remains elusive, it appears that there is chronic activation of the immune and inflammatory cascade in genetically susceptible individuals. Current disease management guidelines have therefore focused on the use of anti-inflammatory...

  • Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. de Mattos, Bruno Rafael Ramos; Garcia, Maellin Pereira Gracindo; Nogueira, Julia Bier; Paiatto, Lisiery Negrini; Albuquerque, Cassia Galdino; Souza, Caique Lopes; Fernandes, Luís Gustavo Romani; Tamashiro, Wirla Maria da Silva Cunha; Simioni, Patricia Ucelli // Mediators of Inflammation;8/3/2015, Vol. 2015, p1 

    Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn’s disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due...

  • Corticosteroids.  // Reactions Weekly;1/12/2008, Issue 1184, p14 

    The article describes the case of four patients with inflammatory bowel disease and who developed steroid allergy during treatment with corticosteroids. Three patients, a 40-year old man with Crohn's disease, a 53-year old woman and a 39-year old man both with ulcerative colitis, developed...

  • Budesonide: Teaching an Old Dog New Tricks for Inflammatory Bowel Disease Treatment. Angelucci, Erika; Malesci, Alberto; Danese, Silvio // Current Medicinal Chemistry;2008, Vol. 15 Issue 24, p2527 

    Crohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative...

  • Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p78 

    This excellent review summarizes the current challenges in IBD clinical trials and gives a rational series of recommendations for improvements.

  • AGA Reviews the Use of Corticosteroids, Immunomodulators, and Infliximab in IBD. Graham, Lisa // American Family Physician;2/1/2007, Vol. 75 Issue 3, p410 

    The article focuses on the guidance issued by the American Gastroenterological Association (AGA) on the use of corticosteroids, immunomodulators and infliximab in the treatment of inflammatory bowel disease (IBD). Budesonide can be given to patients with mild to moderate IBD but should not be...

  • Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease. Argüelles-Arias, F.; Castro-Laria, L.; Lobatón, T.; Aguas-Peris, M.; Rojas-Feria, M.; Barreiro-de Acosta, M.; Soto-Escribano, P.; Calvo-Moya, M.; Ginard-Vicens, D.; Chaparro-Sánchez, M.; Hernández-Durán, M.; Castro-Senosiain, B.; Fernández-Villaverde, A.; García-Sánchez, V.; Domínguez-Muñoz, E.; Caunedo-Álvarez, A.; Herrerías-Gutiérrez, J. // Digestive Diseases & Sciences;Oct2013, Vol. 58 Issue 10, p2949 

    Background: Pyoderma gangrenosum is a serious cutaneous complication seen in approximately 1 % of patients with inflammatory bowel disease (IBD). Oral corticosteroids are the mainstay treatment, although the evidence supporting their use is weak. Aims: The purpose of this study was to...

  • Where the Rubber Meets the Road. WEINER, GARY // Naturopathic Doctor News & Review;Jan2014, Vol. 10 Issue 1, p1 

    The article focuses on treatment of inflammatory bowel disease (IBD), one of the five most prevalent gastrointestinal diseases in the U.S. IBD is comprised of ulcerative colitis (UC) and Crohn's disease (CD). It states that IBD is without a medical cure and often requires a lifetime of care. The...

  • Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases. Brassard, Paul; Sinyavskaya, Liliya; Patenaude, Valerie; Suissa, Samy; Bitton, Alain; Suissa, Alain // American Journal of Gastroenterology;Nov2014, Vol. 109 Issue 11, p1795 

    OBJECTIVES:Systemic corticosteroids are among the most common anti-inflammatory treatments in elderly-onset inflammatory bowel disease (IBD) patients. Steroid use and older age each independently predisposes to infections, and infections increase mortality in hospitalized older IBD patients....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics